Alzheimer's drug approvals create prescribing dilemmas.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39480935.
- Also identified by DOI 10.1126/science.adu2383.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinicians and patients weigh modest benefits of the antibodies against sometimes-serious side effects.
Medical subject headings
- Alzheimer Disease
- Antibodies, Monoclonal, Humanized
- Drug Approval
- United States Food and Drug Administration
- Drug Prescriptions